gnckКолопроктологияKoloproktologia2073-75562686-7303Russian Association of Coloproctology10.33878/2073-7556-2025-24-2-42-51gnck-2003Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESСравнительная оценка эффективности упадацитиниба и тофацитиниба в течение одного года при язвенном колите в реальной клинической практикеEffectiveness of upadacitinib and tofacitinib for one year in ulcerative colitis in real clinical practicehttps://orcid.org/0000-0003-2013-8798БарановаТ. А.BaranovaT. A.

Баранова Татьяна Алексеевна — врач-гастроэнтеролог гастроэнтерологического отделения.

Ул. Саляма Адиля, д. 2, Москва, 123423

Tatiana A. Baranova

Salyama Adilya st., 2, Moscow, 123423

baranova_ta@gnck.ruhttps://orcid.org/0009-0005-1182-419XИгнатенкоM. А.IgnatenkoM. A.

Игнатенко Мария Андреевна — специалист отдела планирования и организации научных исследований.

Ул. Саляма Адиля, д. 2, Москва, 123423

Maria A. Ignatenko

Salyama Adilya st., 2, Moscow, 123423

https://orcid.org/0000-0002-8803-7566ВыковаБ. А.VykovaB. A.

Александров Тимофей Леонидович — к.м.н., научный сотрудник отдела по изучению воспалительных и функциональных заболеваний кишечника.

Ул. Саляма Адиля, д. 2, Москва, 123423

Bella A. Vykova

Salyama Adilya st., 2, Moscow, 123423

https://orcid.org/0000-0003-1697-4670АлександровТ. Л.AlexandrovT. L.

Выкова Бэлла Александровна — к.м.н., заведующая гастроэнтерологическим отделением.

Ул. Саляма Адиля, д. 2, Москва, 123423

Timofey L. Alexandrov

Salyama Adilya st., 2, Moscow, 123423

https://orcid.org/0009-0000-8634-731XСергееваК. А.SergeevaK. A.

Сергеева Кристина Анатольевна — младший научный сотрудник отдела по изучению воспалительных и функциональных заболеваний кишечника.

Ул. Саляма Адиля, д. 2, Москва, 123423

Kristina A. Sergeeva

Salyama Adilya st., 2, Moscow, 123423

ФГБУ «НМИЦ колопроктологии имени А.Н. Рыжих» Минздрава РоссииРоссияRyzhikh National Medical Research Center of ColoproctologyRussian Federation2025170520252424251Copyright © Баранова Т.А., Игнатенко M.А., Выкова Б.А., Александров Т.Л., Сергеева К.А., 20252025Баранова Т.А., Игнатенко M.А., Выкова Б.А., Александров Т.Л., Сергеева К.А.Baranova T.A., Ignatenko M.A., Vykova B.A., Alexandrov T.L., Sergeeva K.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ruproctology.com/jour/article/view/2003ЦЕЛЬ

ЦЕЛЬ: сравнить эффективность в течение одного года упадацитиниба (УПА) и тофацитиниба (ТОФА) при среднетяжелой и тяжелой атаках язвенного колита (ЯК).

ПАЦИЕНТЫ И МЕТОДЫ

ПАЦИЕНТЫ И МЕТОДЫ: проведен ретроспективный анализ электронной медицинской документации пациентов, которые были инициированы УПА и ТОФА для лечения ЯК в период с января 2022 по январь 2023 гг. В анализ включено 74 пациента (по 37 в каждой группе). У всех пациентов оценивались демографические показатели, проводился анализ тяжести атаки с учетом частичного индекса Мейо, лабораторных показателей, эндоскопических результатов на начало терапии (0 день), на 8-й, 26-й и 56-й неделе терапии, частоты и характера нежелательных реакций на период проведения терапии. С целью создания сопоставимых групп по эндоскопической активности до начала терапии был применен метод оптимального подбора пар.

РЕЗУЛЬТАТЫ

РЕЗУЛЬТАТЫ: эндоскопический ответ зарегистрирован у 10/34 (29%) пациентов в группе ТОФА и 18/36 (50%) на УПА (p = 0,08) при оценке изменений эндоскопической картины между 8 и 0 неделями терапии; у 14/30 (47%) на ТОФА и 13/29 (45%) на УПА (p = 0,9) между 26 и 8 неделями; у 6/26 (23%) на ТОФА и 13/28 (46%) на УПА (p = 0,09) между 56 и 26 неделями, соответственно. В группах ТОФА и УПА эндоскопическая ремиссия к 56-й неделе была достигнута у 18/26 (69%) пациентов и 15/28 (54%) пациентов, соответственно. Анализ вторичных результатов не выявил статистически значимой разницы между 2 группами в отношении оптимизации терапии или необходимости хирургического лечения. Лабораторные показатели, как и тяжесть течения ЯК, не различались между группами во всех временных контрольных точках.

ЗАКЛЮЧЕНИЕ

ЗАКЛЮЧЕНИЕ: эндоскопический ответ и ремиссия статистически не различались между двумя группами. Необходимо рандомизированное проспективное исследование для сравнения эффективности упадацитиниба с тофацитинибом.

AIM

AIM: to compare the one-year efficacy of upadacitinib (UPA) and tofacitinib (TOFA) for moderate to severe attacks of ulcerative colitis (UC).

PATIENTS AND METHODS

PATIENTS AND METHODS: a retrospective study included electronic medical records of patients who were initiated by UPA and TOFA for the treatment of UC between January 2022 and January 2023. In consisted of 74 patients (37 in each group). In all patients, demographic data were assessed, the severity of the attack was assessed using the partial Mayo index, laboratory data, endoscopy at the start of therapy (day 0), at the 8th, 26th and 56th week of therapy, the incidence and nature of adverse events for the period of therapy. In order to create comparable groups for endoscopic activity before the start of therapy, the method of optimal pairing was used.

RESULTS

RESULTS: endoscopic response was found in 10/34 (29%) patients in the TOFA group and 18/36 (50%) in the UPA group (p = 0.08) when assessing changes in the endoscopic picture between 8 and 0 weeks of therapy; 14/30 (47%) on TOFA and 13/29 (45%) on UPA (p = 0.9) between 26 and 8 weeks; 6/26 (23%) on TOFA and 13/28 (46%) on UPA (p = 0.09) between 56 and 26 weeks, respectively. In the TOFA and UPA groups, endoscopic remission by week 56 was achieved in 18/26 (69%) patients and 15/28 (54%) patients, respectively. Secondary outcomes data did not reveal a significant difference between the 2 groups regarding optimization of therapy or the need for surgery. Laboratory data, as well as the severity of UC, did not differ between groups at all time control points.

CONCLUSION

CONCLUSION: endoscopic response and remission were not statistically different between the two groups. A randomized, prospective study is needed to compare the efficacy of upadacitinib with tofacitinib.

язвенный колиттофацитинибупадацитинибulcerative colitistofacitinibUpadacitinibисточники финансирования отсутствуютReferencesКлинические рекомендации. Язвенный колит. 2024-2025-2026 (29.05.2024). Утверждены Минздравом РФ. http://disuria.ru/_ld/14/1421_kr24K51MZ.pdfClinical recommendations. Ulcerative colitis. 2024-2025-2026 (05/29/2024). Approved by the Ministry of Health of the Russian Federation. (In Russ.). http://disuria.ru/_ld/14/1421_kr24K51MZ.pdfSingh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: Firstand second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(2):162–75.Singh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: Firstand second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(2):162–75.Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: Ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413.Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: Ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413.O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013; 72(Suppl 2):ii111–ii115.O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013; 72(Suppl 2):ii111–ii115.Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases [published correction appears in Nat Rev Drug Discov. 2017 Dec 28;17(1):78]. Nat Rev Drug Discov. 2017;16(12):843–62Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases [published correction appears in Nat Rev Drug Discov. 2017 Dec 28;17(1):78]. Nat Rev Drug Discov. 2017;16(12):843–62Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36.Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36.Núñez P, Quera R, Yarur AJ. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases. Drugs. 2023 Mar;83(4):299–314. doi: 10.1007/s40265-023-01840-5 Epub 2023 Mar 13. PMID: 36913180; PMCID: PMC10010235.Núñez P, Quera R, Yarur AJ. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases. Drugs. 2023 Mar;83(4):299–314. doi: 10.1007/s40265-023-01840-5 Epub 2023 Mar 13. PMID: 36913180; PMCID: PMC10010235.Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66(2):199–209Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66(2):199–209Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42(4):759–773.Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42(4):759–773.Mohamed MF, Camp HS, Jiang P, et al. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547–1558.Mohamed MF, Camp HS, Jiang P, et al. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547–1558.Boneschansker L, Ananthakrishnan AN. Massachusetts General Hospital Crohn’s and Colitis Center Collaborators. Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: Real-world data. Clin Gastroenterol Hepatol. 2023;21(9):2427–9.e1.Boneschansker L, Ananthakrishnan AN. Massachusetts General Hospital Crohn’s and Colitis Center Collaborators. Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: Real-world data. Clin Gastroenterol Hepatol. 2023;21(9):2427–9.e1.Dalal RS, Kallumkal G, Cabral HJ, et al. One-year comparative effectiveness of upadacitinib vs tofacitinib for ulcerative colitis: A multicenter cohort study. Am J Gastroenterol. 2024 Apr 1. doi: 10.14309/ajg.0000000000002746Dalal RS, Kallumkal G, Cabral HJ, et al. One-year comparative effectiveness of upadacitinib vs tofacitinib for ulcerative colitis: A multicenter cohort study. Am J Gastroenterol. 2024 Apr 1. doi: 10.14309/ajg.0000000000002746Panaccione R, Collins EB, Melmed GY, et al. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: An indirect treatment comparison using Bayesian network meta-analysis. Crohns Colitis. 360 2023;5(2):otad009.Panaccione R, Collins EB, Melmed GY, et al. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: An indirect treatment comparison using Bayesian network meta-analysis. Crohns Colitis. 360 2023;5(2):otad009.Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–70.Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–70.Din S, Selinger C, Black C, et al. Systematic review with network meta-analysis: Risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(6):666–75.Din S, Selinger C, Black C, et al. Systematic review with network meta-analysis: Risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(6):666–75.Herrera-deGuise C, Serra-Ruiz X, Lastiri E, et al. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front Med. 2023;10:1089099.Herrera-deGuise C, Serra-Ruiz X, Lastiri E, et al. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front Med. 2023;10:1089099.Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–26.Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–26.Yang V, Kragstrup TW, McMaster C, et al. Managing cardiovascular and cancer risk associated with JAK inhibitors. Drug Saf. 2023;46(11):1049–71.Yang V, Kragstrup TW, McMaster C, et al. Managing cardiovascular and cancer risk associated with JAK inhibitors. Drug Saf. 2023;46(11):1049–71.Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: A post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82(1):119–29.Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: A post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82(1):119–29.Curtis JR, Yamaoka K, Chen YH, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82(3):331–43.Curtis JR, Yamaoka K, Chen YH, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82(3):331–43.Yates M, Mootoo A, Adas M, et al. Venous thromboembolism risk with JAK inhibitors: A meta-analysis. Arthritis Rheumatol. 2021;73(5):779–88.Yates M, Mootoo A, Adas M, et al. Venous thromboembolism risk with JAK inhibitors: A meta-analysis. Arthritis Rheumatol. 2021;73(5):779–88.Afzali A, Lukanova R, Hennessy F, et al. Unmet needs in realworld advanced therapy-naïve and -experienced patients with moderately to severely active ulcerative colitis in the United States. Adv Ther. 2023;40(10):4321–38.Afzali A, Lukanova R, Hennessy F, et al. Unmet needs in realworld advanced therapy-naïve and -experienced patients with moderately to severely active ulcerative colitis in the United States. Adv Ther. 2023;40(10):4321–38.Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials [published correction appears in Lancet. 2022 Sep 24;400(10357):996]. Lancet. 2022;399(10341):2113–28.Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials [published correction appears in Lancet. 2022 Sep 24;400(10357):996]. Lancet. 2022;399(10341):2113–28.Danese S, Argollo M, Le Berre C, et al. JAK selectivity for inflammatory bowel disease treatment: Does it clinically matter? Gut. 2019;68(10):1893–9.Danese S, Argollo M, Le Berre C, et al. JAK selectivity for inflammatory bowel disease treatment: Does it clinically matter? Gut. 2019;68(10):1893–9.Fensome A, Ambler CM, Arnold E, et al. Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: Discovery of ((S)-2,2-difluorocyclopropyl) ((1 R,5 S)-3-(2-((1-methyl-1Hpyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo [3.2.1] octan8-yl) methanone (PF-06700841). J Med Chem. 2018;61(19):8597– 612.Fensome A, Ambler CM, Arnold E, et al. Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: Discovery of ((S)-2,2-difluorocyclopropyl) ((1 R,5 S)-3-(2-((1-methyl-1Hpyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo [3.2.1] octan8-yl) methanone (PF-06700841). J Med Chem. 2018;61(19):8597– 612.Белоусова Е.А., Абдулганиева Д.И., Алексеева О.П., и соавт. Опыт применения тофацитиниба в терапии язвенного колита в условиях реальной клинической практики. Колопроктология. 2019;18(4):86–99. doi: 10.33878/2073-7556-2019-18-4-86-99Belousova E.A., Abdulganieva D.I., Alekseeva O.P., et al. Experience of tofacitinib using in therapy of ulcerative colitis in real clinical practice. Koloproktologia. 2019;18(4):86–99. (In Russ.). doi: 10.33878/2073-7556-2019-18-4-86-99Подольская Д.В., Шапина М.В., Баранова Т.А., и соавт. Эффективность тофацитиниба в качестве «терапии спасения» у пациентов с язвенным колитом тяжелой степени. Колопроктология. 2021;20(3):43–50. doi: 10.33878/2073-75562021-20-3-43-50Podolskaya D.V., Shapina M.V., Baranova T.A., et al. Efficacy of tofacitinib as a «rescue therapy» in patients with severe ulcerative colitis. Koloproktologia. 2021;20(3):43–50. (In Russ.). doi: 10.33878/2073-7556-2021-20-3-43-50

The authors declare that there are no conflicts of interest present.